Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Alzheimer’s Disease Diagnostic Market CAGR Analysis And Future Market Development

The global market for Alzheimer’s disease diagnostics has experienced significant expansion, projected to increase from \$7.26 billion in 2025 to \$8.03 billion in 2026, reflecting a compound annual growth rate of 10.6%. This upward trajectory in the historical period is largely due to the escalating incidence of Alzheimer’s disease, heightened public consciousness regarding neurodegenerative conditions, the expanding use of MRI and PET imaging techniques, the proliferation of diagnostic facilities and healthcare institutions, and increased funding dedicated to research in cognitive assessment.

The market for Alzheimer’s disease diagnostics is poised for significant expansion, projected to reach $11.89 billion by the year 2030, reflecting a compound annual growth rate of 10.3%. This anticipated surge is fueled by advancements in novel biomarkers and imaging tracers, the incorporation of artificial intelligence for earlier identification, increased governmental and private investment in Alzheimer’s research, broader adoption of personalized medicine strategies, and an uptick in multi-center clinical trials. Key developments anticipated during this forecast period encompass a greater reliance on diagnostics that utilize biomarkers, enhanced application of neuroimaging techniques for early detection, an escalation in cognitive assessment testing, expanded genetic testing to evaluate Alzheimer’s risk, and the integration of comprehensive, multi-modal diagnostic methodologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21093&type=smp

Alzheimer’s Disease Diagnostic Market Development Factors: Which Trends Are Supporting Demand?

Anticipated expansion in the prevalence of chronic illnesses is poised to spur the advancement of the Alzheimer’s disease diagnostic market. Conditions like heart disease, diabetes, and high blood pressure are significantly linked to a heightened susceptibility to Alzheimer’s and other forms of dementia, consequently boosting the need for diagnostic tools that offer early and precise identification. A primary contributor to this surge in chronic ailments is the pervasive adoption of sedentary habits, as substantial public health studies consistently reveal substantially elevated incidences of conditions such as diabetes and cardiovascular issues within populations that are not physically active. Diagnostic tools for Alzheimer’s offer valuable support to healthcare frameworks by permitting early identification, enabling prompt therapeutic actions, and assisting in the management of patients to potentially decelerate the disease’s advancement. To illustrate, in November 2023, data from Heritage Health Services, a US non-profit health research entity, indicated that 6.7 million individuals over 65 in the United States were coping with Alzheimer’s dementia, with the condition becoming more widespread with advancing age, affecting 5.0% of those aged 65–74, 13.1% of those aged 75–84, and 33.3% of those aged 85 and older. This figure is forecasted to approach 13 million by the year 2050, underscoring how the increasing burden of chronic disease is fueling the growth trajectory of the Alzheimer’s disease diagnostic market.

#Alzheimer’s Disease Diagnostic Market Segment Landscape And Growth Potential

The alzheimer’s disease diagnostic market covered in this report is segmented –

1) By Type: Triage, Diagnosis, Screening

2) By Diagnostic Technique: Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests

3) By End User: Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, Academic Research Center

Subsegments:

1) By Triage: Cognitive Testing, Imaging Techniques

2) By Diagnosis: Biomarker Testing, Neuroimaging

3) By Screening: Neuropsychological Testing, Genetic Testing

Alzheimer’s Disease Diagnostic Market Transformation Trends: Which Innovations Are Driving Change?

Key players within the Alzheimer’s disease diagnostics sector are directing their efforts toward the development of blood-based biomarker assays, a strategic move anticipated to streamline the diagnostic pathway for Alzheimer’s, thereby lessening the dependence on more intrusive methods and enhancing the availability of prompt therapeutic interventions for individuals affected. Illustrating this trend, Quanterix, a biotechnology firm based in the United States, introduced the LucentAD p-Tau 217 test in October 2023, a blood-based indicator of Alzheimer’s pathology that exhibits considerable clinical sensitivity and specificity. Conventional diagnostic avenues for cerebrospinal fluid (CSF) biomarkers, such as positron emission tomography (PET) scans or lumbar punctures, are characterized by their expense, invasive nature, and limited accessibility. The LucentAD test further integrates Quanterix’s highly sensitive SimoaÒ technology with well-validated p-Tau 217 antibodies sourced from J&J Innovative Medicine, ensuring superior precision and a more user-friendly procedure.

Alzheimer’s Disease Diagnostic Market Competitive Landscape: Who Are The Leading Companies?

Major companies operating in the alzheimer’s disease diagnostic market are Hoffmann-La Roche, Eli Lilly and Company, Quest Diagnostics Incorporated, Laboratory Corporation of America Holdings, Lantheus, Quanterix, C2N Diagnostics, Sysmex, Royal Philips, Bruker Corporation, Revvity, Alamar Biosciences, ADx Neurosciences, Randox Laboratories, DiaSorin, Shenzhen Mindray Bio-Medical Electronics, Nipro Corporation, Canon Inc, Hitachi Ltd, Eisai Co Ltd

Access The Complete Alzheimer’s Disease Diagnostic Market Report:

https://www.thebusinessresearchcompany.com/report/alzheimers-disease-diagnostic-global-market-report

#Alzheimer’s Disease Diagnostic Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the alzheimer’s disease diagnostic market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the alzheimer’s disease diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model